Entrada Therapeutics is finally able to get its Duchenne muscular dystrophy candidate (DMD) back on track after the FDA ...

Entrada Therapeutics gains FDA clearance for its Phase 1b ELEVATE-44-102 study, evaluating ENTR-601-44 in adult Duchenne ...

Shares of Entrada Therapeutics rose after regulators removed a clinical hold and said its lead product candidate could be studied as a treatment for Duchenne muscular dystrophy. The stock was up 9.5% ...

Receives FDA authorization to initiate ELEVATE-44-102, a Phase 1b multiple ascending dose clinical study of ENTR-601-44 in adults living with ...

The American Heart Association was honored to have local heart hero Mac Gohagan share his remarkable story with students at ...

Capricor Therapeutics filed a BLA for deramiocel, showing promising results in slowing cardiac dysfunction in DMD ...

I'm fighting a fatal disease that took the life of my brother. I work in biotech and know there are medical advances that ...

Families and doctors spoke out against the cuts at a roundtable at the UMass Chan Medical School in Worcester, Massachusetts.

A new study from the University of Ottawa’s Faculty of Medicine sheds light on a potential breakthrough in treating muscle ...

Telangana's Chief Minister, Revanth Reddy, has intervened to assist Rakesh, a student afflicted with Pseudo Muscular ...